Dear reader,
This issue of Human Vaccines & Immunotherapeutics begins with seven articles on Immunotherapy, including a review of antigen-specific immunotherapies for renal cell carcinoma (Xu, p 1882), a mini-review of immunotherapeutic approaches to fight Covid-19 (Iqbal Yatoo, p 1897), preclinical studies on the synergistic effects of PD-L1 inhibition and peptide vaccines in melanoma (Ji, p 1910), and tolerance-inducing nanoparticle vaccine for prevention of vitiligo (Zhang, p 1923), two commentaries on the role of cholesterol metabolism on checkpoint inhibition cancer therapy (Bersanelli, p 1930) and on clinical trials testing immune checkpoint inhibition in rare tumors (Mittra, p 1935), and a Letter to the Editor on exacerbation of tuberculosis as an adverse effect of checkpoint inhibition immunotherapy (Kubo, p 1940).
The HPV segment features cost-effectiveness analysis of expanded catch-up vaccination in adults (Daniels, p 1943), assessment of the impact of educational intervention on students’ vaccine knowledge (Berenson, p 1952), a survey among primary-care physicians on vaccine hesitancy and recommendations (Tsui, p 1961), examination of vaccine acceptability among medical students (Farsi, p 1968), a commentary on school-entry requirements (Thompson, p 1975), and immunogenicity and safety trial of HPV-9 in Vietnamese children and young adults (Thiem, p 1980).
The Acceptance section presents studies on practices and perceptions of non-medical exemptions following their ban in California (Holroyd, p 1986), the impact of hesitancy screening on future acceptance (Cunningham, p 1994), trends in the classification of reasons for hesitancy (Kulkarni, p 2001), ethnic determinants of vaccine completion in Nigeria (Afolabi, p 2008), hesitancy among healthcare providers in United Arab Emirates (Elbarazi, p 2018), vaccine misinformation on social media in Poland (Klimiuk, p 2026), and determinants of uptake in HIV-affected families in India (Arya, p 2036).
Fourteen articles on Licensed Vaccines investigate social determinants of herpes zoster vaccine compliance in older adults (Shuovo, p 2043), safety and efficacy of the adjuvanted recombinant zoster vaccine in Asian adults (Kim, p 2050), adjuvant effects of exercise in young people (Lee, p 2058), vaccination practices in children with congenital heart disease in China (Li, p 2065), waning immunity following mumps vaccination (Wang, p 2072), seroprevalence and persistence following measles vaccination and infection in Italy (Bianchi, p 2078), pandemic lessons from measles outbreaks (a commentary by Stein-Zamir, p 2085), safety and efficacy of rabies immunoglobulin in children (Hobart-Porter, p 2090), impact of EV71 vaccination on encephalitis in HFMD patients (Li, p 2097), the validity of test-negative design of EV71 vaccine trials (Zhang, p 2101), immunogenicity and safety of a booster dose of 4-valent dengue vaccine (Park, p 2107), surveillance of vaccine-derived polio (Odoom, p 2117), immunogenicity of different polio vaccine regimens (Xu, p 2125), and a Letter to the Editor on the introduction of typhoid vaccine in Pakistan (Aslam, p 2132).
The Clinical segment features a survey of views on vaccinomics following discussion with experts (Gerber, p 2133), evaluation of adverse events following vaccination in national campaigns in Turkey (Şimşek, p 2145), and a commentary on conducting Phase 3 trials in resource-limited settings (Saluja, p 2149).
Five Influenza-related articles review utility of cell-based vaccines in the Islamic world (Zulkarnain, p 2158), and report on the association of previous vaccination with Covid-19 (Green, p 2169), pregnant women’s views of the disease and vaccination (Arriola, p 2176), improved vaccine coverage among Chinese healthcare workers (Yi, p 2185), and the link between vaccine awareness and acceptance in Saudi Arabia (Al Hassan, p 2190).
The Meningococcal section introduces reviews on vaccination in China (Xu, p 2197), immune responses to MenC following 1- and 4-valent vaccination (Serra, p 2205), and vaccination during mass gatherings in India (Dubey, p 2216), and a study on cross-reactivity of MenB-specific antibodies (Fazio, p 2216).
Three Pneumococcal studies report on cost-effectiveness of PCV-13 in US adults (Kobayashi, p 2232) and Chinese young children (Wang, p 2241), and safety and immunogenicity of two novel conjugate vaccines (Fitz-Patrick, p 2249).
The Hepatitis segment includes a report on regional differences in discrimination against disease carriers in rural China (Li, p 2257), a study of determinants of long-term immune protection from HBV (Mastrodomenico, p 2268), and a review of the risk of multiple sclerosis following HBV vaccination (Sestili, p 2273).
The Coronavirus section presents surveys of willingness to receive a Covid-19 vaccine (Chen, p 2279) and the influenza vaccine following the pandemic experience (Zhou, p 2289), and a commentary on the implications of disease spread dynamics on vaccine development (Mosa, p 2293).
Two articles on Rotavirus highlight the development of a live attenuated vaccine for use in LMICs (Kumar, p 2298), and safety and immunogenicity of a novel oral hexavalent vaccine (Wu, p 2311).
Research in Public Health explores the link between the density of vaccine workers and coverage in China (Hu, p 2319), and factors associated with vaccine coverage of one-year-olds in Ethiopia (Biset, p 2326).
Finally, we are happy to introduce a preclinical trial of a Novel Vaccine adjuvant based on straight polyacrylate (Pavot, p).
Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section, we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!
Sincerely,
Ronald Ellis, PhD
Editor-in-Chief
Adam Weiss, PhD
Acquisitions Editor